Original ArticlesResults of operation in Mycobacterium avium-intracellulare lung disease
Section snippets
Material and methods
Surgical records of The University of Texas Health Center were screened retrospectively for all patients who had undergone thoracic operation for MAC disease between January 1, 1989, and June 30, 1997. Clinical and microbiological records on the identified patients were then reviewed. Patients were included if they had undergone thoracic operation for MAC lung disease, had multiple positive sputa for MAC, and met the recent American Thoracic Society criteria for lung disease due to the NTM [6].
Patients
Between January 1, 1989, and June 30, 1997, 28 patients with MAC lung disease underwent a thoracic operation. None of these patients were known to be or suspected of being positive for human immunodeficiency virus. These patients were part of more than 300 patients with proven or suspected MAC disease seen or evaluated by the medical service during this time period. Many were enrolled in multidrug treatment trials approved by the Institutional Human Subjects Investigational Committee that began
Comment
Operation continues to play an important role in the management of fibrocavitary M avium-intracellulare lung disease even with the development of newer, better drugs such as clarithromycin. Currently it appears that better than 90% of patients who undergo resection can achieve permanent control of their disease. Timing of surgical intervention is still problematic, and no real recommendations for who to operate on and when have been set forth for this disease.
The use of muscle flaps are
References (11)
- et al.
Surgical management of resistant mycobacterial tuberculosis and other mycobacterial pulmonary infections
Ann Thorac Surg
(1991) - et al.
Surgery in the treatment of multidrug-resistant tuberculosis
Clin Chest Med
(1997) - Ostroff S, Hutwagner L, Collin S. Mycobacterial species and drug resistance patterns reported by state...
- et al.
Clarithromycin therapy for bacteremic Mycobacterium avium complex disease
Ann Intern Med
(1994) - et al.
Clarithromycin regimens for pulmonary Mycobacterium avium complex
Am J Respir Crit Care Med
(1996)
Cited by (82)
Surgical Treatment of Nontuberculous Mycobacterial Pulmonary Disease and a Combination of Nontuberculous Mycobacterium Pulmonary Disease and Pulmonary Tuberculosis
2022, International Journal of Infectious DiseasesNontuberculous Mycobacterial Infections
2022, Radiologic Clinics of North AmericaNontuberculous Mycobacteria: Diagnosis and Therapy
2022, Clinics in Chest MedicineCitation Excerpt :Surgical outcomes are typically favorable, with more than 90% of patients achieving culture conversion postoperatively.109–116 Complications, however, are seen in approximately one-third of patients, and include pneumothorax, prolonged air leak, and bronchopleural fistula.109–116 Before starting therapy for NTM pulmonary disease, patients should have baseline laboratory tests (complete metabolic panel, complete blood count with differential, and C-reactive protein), chest CT scan, and susceptibility testing on the NTM isolate performed.1,2
Extensive Lung Resection for Nontuberculous Mycobacterial Lung Disease With Multilobar Lesions
2021, Annals of Thoracic Surgery